S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
The single greatest medical breakthrough of all time? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Closing prices for crude oil, gold and other commodities
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
The single greatest medical breakthrough of all time? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Closing prices for crude oil, gold and other commodities
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
The single greatest medical breakthrough of all time? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Closing prices for crude oil, gold and other commodities
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
The single greatest medical breakthrough of all time? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Closing prices for crude oil, gold and other commodities
NASDAQ:BDRX

Biodexa Pharmaceuticals (BDRX) Stock Forecast, Price & News

$4.99
-0.12 (-2.35%)
(As of 09/29/2023 ET)
Compare
Today's Range
$4.83
▼
$5.33
50-Day Range
$4.76
▼
$7.99
52-Week Range
$3.51
▼
$768.00
Volume
64,294 shs
Average Volume
302,533 shs
Market Capitalization
$6.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media

BDRX stock logo

About Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

BDRX Price History

BDRX Stock News Headlines

September 27, 2023 | americanbankingnews.com
Critical Contrast: Biodexa Pharmaceuticals (NASDAQ:BDRX) and Genmab A/S (NASDAQ:GMAB)
September 21, 2023 | finance.yahoo.com
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
September 30, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
August 15, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday's Session
July 28, 2023 | finanznachrichten.de
Biodexa Pharmaceuticals PLC: Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
July 28, 2023 | finance.yahoo.com
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
July 24, 2023 | marketwatch.com
ADRs End Mostly Higher; Steakholder Foods, Biodexa Pharmaceuticals Trade Actively
July 24, 2023 | finanznachrichten.de
Biodexa Pharmaceuticals PLC: Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
September 30, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
July 24, 2023 | finance.yahoo.com
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
July 20, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Rise Modestly Thursday
July 10, 2023 | finance.yahoo.com
Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)
July 6, 2023 | finance.yahoo.com
Results of Appeal of Delisting Determination
July 6, 2023 | finance.yahoo.com
Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)
July 6, 2023 | finance.yahoo.com
Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)
June 23, 2023 | finanznachrichten.de
Biodexa Pharmaceuticals PLC: ADR Ratio Change
June 22, 2023 | finance.yahoo.com
ADR Ratio Change
June 20, 2023 | finanznachrichten.de
Biodexa Pharmaceuticals PLC: Appeal of Delisting Determination
June 20, 2023 | finance.yahoo.com
Appeal of Delisting Determination
June 16, 2023 | finanznachrichten.de
Biodexa Pharmaceuticals PLC: Receipt of NASDAQ Delisting Determination Plans to Appeal
June 15, 2023 | seekingalpha.com
BDRX receives Nasdaq delisting notice, plans to appeal decision
June 15, 2023 | finance.yahoo.com
Receipt of NASDAQ Delisting Determination Plans to Appeal
June 14, 2023 | finanznachrichten.de
Biodexa Pharmaceuticals PLC: Results of Annual General Meeting and General Meeting
June 14, 2023 | finance.yahoo.com
Results of Annual General Meeting and General Meeting
June 1, 2023 | msn.com
Why LL Flooring Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
May 26, 2023 | finance.yahoo.com
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
May 24, 2023 | finance.yahoo.com
Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering
See More Headlines
Receive BDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BDRX Company Calendar

Today
9/30/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BDRX
CUSIP
N/A
CIK
1643918
Web
www.midatechpharma.com
Phone
441235888300
Fax
N/A
Employees
27
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.15
Current Ratio
2.47
Quick Ratio
2.47

Sales & Book Value

Annual Sales
$870,000.00
Price / Sales
7.40
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$57.76 per share
Price / Book
0.09

Miscellaneous

Outstanding Shares
1,290,000
Free Float
1,283,000
Market Cap
$6.44 million
Optionable
Not Optionable
Beta
1.95
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Stephen A. Stamp (Age 61)
    CEO, CFO, Company Sec. & Director
    Comp: $294.63k
  • Dr. Dmitry Zamoryakhin M.D. (Age 43)
    Chief Scientific Officer
    Comp: $293.12k
  • Dr. Daniel Palmer MBA
    Ph.D., VP of Technology
  • Mr. Vincent Holmes
    VP & Head of Clinical Operations
  • Ms. Fiona Sharp
    Group Financial Controller

Key Competitors

View All Competitors













BDRX Stock - Frequently Asked Questions

How have BDRX shares performed in 2023?

Biodexa Pharmaceuticals' stock was trading at $33.7360 at the start of the year. Since then, BDRX stock has decreased by 85.2% and is now trading at $4.99.
View the best growth stocks for 2023 here.

Are investors shorting Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 7,700 shares, a decrease of 64.2% from the August 31st total of 21,500 shares. Based on an average daily trading volume, of 665,100 shares, the short-interest ratio is presently 0.0 days.
View Biodexa Pharmaceuticals' Short Interest.

When did Biodexa Pharmaceuticals' stock split?

Shares of Biodexa Pharmaceuticals reverse split on the morning of Wednesday, July 5th 2023. The 1-80 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What is Biodexa Pharmaceuticals' stock symbol?

Biodexa Pharmaceuticals trades on the NASDAQ under the ticker symbol "BDRX."

How do I buy shares of Biodexa Pharmaceuticals?

Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biodexa Pharmaceuticals' stock price today?

One share of BDRX stock can currently be purchased for approximately $4.99.

How much money does Biodexa Pharmaceuticals make?

Biodexa Pharmaceuticals (NASDAQ:BDRX) has a market capitalization of $6.44 million and generates $870,000.00 in revenue each year.

How can I contact Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals' mailing address is 1 CASPIAN POINT CASPIAN WAY, CARDIFF X0, CF10 4DQ. The official website for the company is www.midatechpharma.com. The company can be reached via phone at 441235888300 or via email at ir@midatechpharma.com.

This page (NASDAQ:BDRX) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -